



Insights Into Acute Myeloid Leukemia (AML)

21 May 2021, 15.00 – 18.30 CET

Meeting objectives

- Provide an overview of the current and evolving treatment landscape in adult patients with AML, in the frontline and relapsed/refractory settings
- Understand the need to risk-stratify AML patients to optimize treatment selection on the basis of currently approved agents. Review the clinical data to support use of these agents and optimal management of patients
- Through case-based discussions, understand the appropriate sequencing of available agents to maximize the clinical outcomes of AML patients

Chair: Adriano Venditti, MD

Speakers:

Claudio Cerchione, MD, PhD

Richard Schlenk, MD

Elisa Buzzatti, MD

Pau Montesinos, MD, PhD

| Time (CET) | Topic |
|-------------------|---|
| 15.00 (10 min) | Introduction <ul style="list-style-type: none"> • Program overview • Baseline ARS questions |
| 15.10 (15 min) | First-Line Treatment of AML <ul style="list-style-type: none"> • Overview of current data <ul style="list-style-type: none"> - Factors guiding first-line therapy <ul style="list-style-type: none"> ▪ Impact of age, cytogenetics, molecular markers, comorbidities, PS, and etiology (primary, therapy-related, myelodysplasia-related changes) on induction therapy selection - Integration of novel agents approved and under investigation (FLT3 inhibitors, BCL2 inhibitors, Hedgehog pathway inhibitors, IDH1 inhibitors) - Role of MRD - Maintenance therapy |
| 15.25 (95 min) | First-Line Treatment of AML <ul style="list-style-type: none"> • Patient case presentations and discussion, with ARS questions <ul style="list-style-type: none"> - <i>FLT3</i> mutation, eligible for intensive chemo - Intermediate risk, eligible for intensive chemo - Unfavorable risk, eligible for intensive chemo - No actionable mutations, not eligible for intensive chemo |

| | |
|-------------------|---|
| 17.00 (15 min) | Break |
| 17.15 (15 min) | Management of Relapsed/Refractory AML and Promising Strategies <ul style="list-style-type: none"> • Baseline ARS questions • Overview of current data <ul style="list-style-type: none"> - Factors guiding second-line and subsequent therapy <ul style="list-style-type: none"> ▪ Biomarkers at relapse ▪ Patient age, timing of relapse (<12 months vs ≥12 months), and role of reinduction or HCT ▪ Targeted therapy for <i>FLT3</i>-positive, <i>CD33</i>-positive, and <i>IDH1</i>- or <i>IDH2</i>-positive patients |
| 17.30 (35 min) | Relapsed/Refractory AML <ul style="list-style-type: none"> • Patient case presentations and discussion continued, with ARS questions <ul style="list-style-type: none"> - <i>FLT3</i> mutation, eligible for intensive chemo - Intermediate risk, eligible for intensive chemo |
| 18.05 (20 min) | Key Takeaways and Meeting Evaluation |
| 18.25 (5 min) | Meeting Close |